堅朗五金(002791.SZ)獲得兩項發明專利證書
格隆匯8月12日丨堅朗五金(002791.SZ)宣佈,近日,公司獲得中華人民共和國國家知識產權局頒發的兩項發明專利證書。
其中,“安全鎖和推拉門窗”專利號為ZL 201810123728.1,專利申請日為2018年2月7日,專利授權日為2020年6月16日;“夾持裝置及護”專利號為ZL 201810373755.4,專利申請日為2018年4月24日,專利授權日為2020年7月31日。
公司表示,上述專利的取得是公司堅持持續創新的新成果,有利於進一步完善公司知識產權保護體系,發揮公司自主知識產權優勢,促進技術創新,增強公司的核心競爭力,對公司的生產經營有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.